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Figure 1. A, CT scan before empirical therapy for toxoplasmic encephalitis in an HIV-infected patient. B, CT scan 2.5 years later, after immune
restoration with highly active antiretroviral therapy and 8 months without maintenance therapy for toxoplasmic encephalitis.
Discontinuation of Secondary Prophylaxis
for Toxoplasmic Encephalitis in Human
Immunodeficiency Virus Infection After Immune
Restoration with Highly Active Antiretroviral
Therapy
Toxoplasma gondii is one of the leading causes of neurological
morbidity and mortality in patients with advanced HIV infec-
tion. Effective therapies for primary and secondary prevention
of toxoplasmic encephalitis in HIV infection have been estab-
lished [1, 2]. With the introduction of highly active antiretroviral
therapy (HAART), discontinuation of primary and secondary
prophylaxis for opportunistic infections in patients with HIV
infection and good response to HAART have become a focus
of interest. We describe an HIV-infected patient with toxo-
plasmic encephalitis and excellent response to HAART who
discontinued secondary prophylaxis for toxoplasmosis.
A 26-year-old woman with HIV infection presented to our
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clinic with headache in November 1996. She had acquired HIV
infection in 1986 by needle exchange, and, in the following
years, did not seek regular medical assistance. She had not
received any prophylaxis for opportunistic infections or treat-
ment with antiretroviral drugs. Physical examination showed
no neurological deficits. A CT scan revealed a 2.8-cm diameter
solitary hypodense cerebral lesion with perifocal edema on the
right parietotemporal hemisphere (figure 1A); this lesion was
suspected to be toxoplasmic encephalitis. IgG antibodies to T.
gondii were positive at 34 U/mL, her CD4 cell count was 29/
mm3, and the plasma viral load was 302,000 copies/mL. The
patient was empirically treated with pyrimethamine, sulfadia-
zine, and leucovorin.
Four weeks later, a control CT scan showed regression of
both the cerebral lesion and the perifocal edema. Because of a
severe rash, sulfadiazine was changed to clindamycin, and after
6 weeks, the patient received maintenance therapy. Antiretro-
viral therapy with lamivudine, stavudine, and indinavir was
then started. The response was excellent, and in the following
18 months, the CD4 cell count progressively increased to 11100/
mm3, and her plasma viral load was permanently suppressed
(as measured by an ultrasensitive assay [Amplicor; Roche Di-
agnostic Systems, Rotkreuz, Switzerland]).
After 22 months, the patient insisted that her maintenance
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therapy for toxoplasmic encephalitis be discontinued to reduce
her pill load of 20 tablets a day. At this time, a CT scan showed
a 1.7-cm diameter cerebral lesion with calcification that was
identical to that on a previous CT scan at a 12-month follow-
up. Twelve months after discontinuation of secondary prophy-
laxis for T. gondii infection, the patient had no clinical signs of
relapse, and her CT scan remained unchanged (figure 1B).
Data from observational studies on the discontinuation of
primary prophylaxis for Pneumocystis carinii pneumonia in pa-
tients with persistent CD4 lymphocyte counts 1200/mm3 and
antibodies to T. gondii have shown that no relapses of P. carinii
pneumonia and T. gondii infection occurred [3, 4]. However,
the number of patients with antibodies to T. gondii was too
small to allow for firm conclusions as to whether discontinu-
ation of primary prophylaxis for toxoplasmic encephalitis is
safe.
Discontinuation of maintenance therapy for patients with
established toxoplasmic encephalitis is not recommended [5].
Relapse rates after discontinuation of maintenance therapy, as
reported from the pre-HAART era, may be >50% [2]. However,
secondary prophylaxis for toxoplasmic encephalitis is all but
satisfactory. Rates of breakthrough relapses associated with sul-
fadiazine and pyrimethamine, the most effective drug combi-
nation, are 10%–40%, and rates of drug-limiting toxicity as-
sociated with this combination are 30%–43% [2].
Because of side effects, high pill load, and drug interactions,
discontinuation of maintenance therapy for toxoplasmosis after
immune restoration with HAART is likely to improve the qual-
ity of life in patients with AIDS and to increase adherence to
antiretroviral therapy. Therefore, studies evaluating whether
secondary prophylaxis for toxoplasmic encephalitis may be dis-
continued for selected patients with excellent response to
HAART seem timely.
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Intestinal Involvement by Nontuberculous
Mycobacteria After Heart Transplantation
The prevalence of disease due to nontuberculous mycobac-
teria (NTM) in the United States is 1.8 cases per 100,000 pop-
ulation [1]. In the general population, 5%–10% of mycobacteria
causing infections are NTM, whereas in transplant recipients
NTM cause 25%–40% of all mycobacterial infections [2]. We
describe a case of infection with Mycobacterium avium/Myco-
bacterium intracellulare in a heart transplant recipient and re-
view the literature on disease due to NTM [3–12].
A 56-year-old man underwent orthotopic heart transplan-
tation in June 1990 for ischemic cardiomyopathy. In November
1992, he was admitted to the hospital because of fever (tem-
perature, 397C) during treatment with cyclosporine, azathio-
prine, and deflazacort. Physical examination disclosed a small
epitrochlear node and a tender periumbilical mass. His eryth-
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rocyte sedimentation rate was 92 mm/h. Blood cultures and
serological tests for Brucella, Salmonella, Yersinia, cytomega-
lovirus, and HIV were negative. Ziehl-Neelsen staining of urine
and sputum samples were negative, as were cultures of these
samples on Lo¨wenstein-Jensen medium. Purified protein deriv-
ative skin testing was also negative. A CT scan of the chest
and abdomen revealed enlarged retroperitoneal and mesenteric
lymph nodes.
Biopsy of the epitrochlear node revealed granulomas with
scarce acid-fast bacilli, and culture of the node on Lowe¨nstein-
Jensen medium was negative. Laparotomy showed mesenteric
and retroperitoneal lymphadenopathies. Histopathologic ex-
amination of the nodes demonstrated noncaseating granulo-
matous adenitis, whereas Ziehl-Neelsen staining of the nodes
and culture of the nodes on Lo¨wenstein-Jensen medium were
negative. Azathioprine therapy was discontinued, and the cy-
closporine dose was reduced. Subsequently, the fever subsided,
the erythrocyte sedimentation rate normalized, and lymphad-
enopathies regressed.
The patient remained asymptomatic until December 1993,
when he presented because of abdominal pain and a 5-kg weight
loss. Gastrointestinal examination revealed a distorted duo-
denum with duodenal and jejunal mucosal thickening. An ab-
